JD Health (6618.HK) 2022H1 - A Second Growth Point Is Needed to Reassure Investment Logic
JD Health has turned a profit in 22H1, but it needs a second growth point to "hedge" policy risk and future bottleneck of products revenue growth so as to reassure the logic, outlook, valuation growth